Fig. 3

a Kaplan–Meier chart displaying probability of progression-free survival stratified by CDKN2A/B Wild-Type (blue), heterozygous (green) and homozygous CDKN2A/B deletions (red). The log-rank test (p < 0.0001) showed a significantly shortened time to meningioma progression in patients with either hetero- or homozygous CDKN2A/B deletions. The shadowed areas surrounding the curves display the confidence intervals b Kaplan–Meier chart displaying probability of progression-free survival stratified by CDKN2A/B Wild-Type (blue) and heterozygous or homozygous (brown) CDKN2A/B deletions. c Kaplan–Meier chart displaying probability of progression-free survival stratified by homozygous CDKN2A/B deletions (red) and heterozygous CDKN2A/B deletions (green). The log-rank test (p = 0.032) revealed a slightly significant difference regarding meningioma progression. d Kaplan–Meier chart displaying probability of progression-free survival stratified by CDKN2A/B Wild-Type (blue) and heterozygous (green) CDKN2A/B deletions. The log-rank test (p < 0.0001) revealed a significant shortened time to meningioma progression in those with a heterozygous CDKN2A/B deletion compared to those with a wild-type status. Het, Heterozygous; Hom, Homozygous; WT, Wild-type